Early B-Cell Repopulation in Patients With MS Treated With Rituximab Is Not Predictive of a Risk of Relapse or Clinical Progression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
J Neurol 2022 Jun 02;[EPub Ahead of Print], G Dorcet, H Migné, D Biotti, C Bost, F Lerebours, J Ciron, E TreinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.